Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Salvatore Siena(University of Milan), Atsuo Takashima(National Cancer Center Hospital East), Takeshi Kato(Osaka National Hospital), Marc Van den Eynde(Cliniques Universitaires Saint-Luc), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Yoshito Komatsu(Hokkaido University Hospital), Hisato Kawakami(Kindai University), Marc Peeters(Antwerp University Hospital), Thierry André(Sorbonne Université), Sara Lonardi(Istituto Oncologico Veneto), Kensei Yamaguchi(The Cancer Institute Hospital), Jeanne Tie(Peter MacCallum Cancer Centre), Cristina Grávalos Castro(Research Institute Hospital 12 de Octubre), Hung‐Chih Hsu(Chang Gung University), John H. Strickler(Duke Medical Center), Tae‐You Kim(Seoul National University Hospital), Yongjun Cha(National Cancer Center), Daniel Barrios(Daiichi Sankyo (United States)), Qi Yan(Daiichi Sankyo (United States)), Takahiro Kamio(Daiichi Sankyo (United States)), Kojiro Kobayashi(Daiichi-Sankyo (Japan)), Aislyn Boran(Daiichi Sankyo (United States)), Makito Koga(Daiichi-Sankyo (Japan)), John Allard(Daiichi Sankyo (United States)), Takayuki Yoshino(National Cancer Center Hospital East)
The Lancet Oncology
August 5, 2024
10.1016/s1470-2045(24)00380-2
Cited by 119

Abstract

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita et al.|New England Journal of Medicine|2019|1.9k
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al.|Clinical Cancer Research|2016|1.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al.|The Lancet Oncology|2016|1k
Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Bob T. Li, Egbert F. Smit, Yasushi Goto et al.|New England Journal of Medicine|2021|955
Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate et al.|Cancer Science|2016|698